Intravesical XXXX in combination with @entity1138 as salvage treatment in recurrent non-muscle-invasive @entity150 .

@entity1 @entity1138 @entity189 @entity1139 @entity150 @entity3 @entity136
OBJECTIVES: To evaluate oncological outcomes after combination intravesical therapy with @entity136 (GC) and @entity1138 ( @entity1139 ) in the setting of recurrent non-muscle-invasive @entity150 (NMIBC) after failure of previous intravesical therapy. @entity1 AND METHODS: We retrospectively identified @entity1 with recurrent NMIBC after previous intravesical therapy, who refused or were not candidates for cystectomy, between 2005 and 2011. GC and @entity1139 were sequentially instilled weekly for 6-8  weeks. Data were collected regarding @entity1 demographics, @entity150 history, and number and type of intravesical therapies before GC/ @entity1139 . Outcomes evaluated included time to recurrence and/or progression after GC/ @entity1139 . Recurrence-free outcomes were estimated using the Kaplan-Meier method, and Cox proportional hazards regression models were used to test the association of clinicopathological features with outcomes. RESULTS: In all, 27 @entity1 were identified, 23 with high-risk disease (high-grade or @entity189 in  situ) and four with intermediate-risk disease (multifocal or recurrent low-grade). All @entity1 received prior intravesical therapy, and 17 @entity1 (63%) received multiple courses. Twenty-four @entity1 were treated with BCG. The median (range) disease-free survival of all @entity1 was 15.2 (1.7-39.3) months. Seventeen @entity1 (63%) developed recurrent @entity150 , a median of 15.2  months after therapy. One @entity1 progressed to muscle-invasive disease 5  months after treatment, and one developed @entity3 22  months after treatment. Three @entity1 went on to cystectomy. Ten @entity1 (37%) had no evidence of disease at last follow-up, with a median follow-up of 22.1  months. CONCLUSION: The combination of intravesical GC and @entity1139 could offer durable recurrence-free survival to some @entity1 with recurrent NMIBC who are not candidates for, or refuse, cystectomy.
